David Perry, DO
Cardiovascular Disease · Provo, UTNPI 1295029528
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,961 of the $8,093 with a category attached, or 86.0%. It is spread thinly across 41 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,066 and has fallen 59.8% since, to $831 in 2025.
Across 447 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Pfizer$1K
- Amgen$667
- Actelion Pharmaceuticals US, Inc.$626
- Johnson & Johnson$528
- Boston Scientific$519
- plus $3K from 35 others
What the payments were for
- Travel & lodging$1,12614%
- Food & beverage$6,96186%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 16 | $1,361 |
| Pfizer | 109 | $1,127 |
| Amgen | 34 | $667 |
| Actelion Pharmaceuticals US, Inc. | 42 | $626 |
| Johnson & Johnson | 34 | $528 |
| Boston Scientific | 26 | $519 |
| Novartis | 29 | $493 |
| Merck | 25 | $467 |
| Boehringer Ingelheim | 27 | $438 |
| E.r. Squibb & Sons, L.L.C. | 17 | $260 |
| AstraZeneca | 15 | $213 |
| Lantheus Medical Imaging, Inc. | 6 | $209 |
| Amarin Pharma, Inc. | 13 | $167 |
| Alnylam Pharmaceuticals Inc. | 6 | $111 |
| United Therapeutics Corporation | 5 | $88 |
| Baxter Healthcare | 2 | $84 |
| Bridgebio Pharma, Inc. | 3 | $80 |
| Heartflow, Inc. | 2 | $71 |
| Gilead | 5 | $68 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $62 |
| Impulse Dynamics (USA) Inc. | 2 | $50 |
| Masimo Corporation | 3 | $44 |
| Inspire Medical Systems, Inc. | 3 | $43 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $32 |
| Bayer | 2 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Edwards Lifesciences | 1 | $20 |
| Cvrx, Inc. | 1 | $19 |
| Cardinal Health 200 LLC | 1 | $19 |
| Medtronic | 1 | $18 |
| Organon | 1 | $17 |
| Chiesi USA, Inc. | 1 | $17 |
| Sanofi | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Teleflex LLC | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Analog Devices Inc. | 1 | $14 |
| Biotronik Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Novo Nordisk | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$1,001
How this compares
$8,093 in reported general payments places this provider in the 75th percentile of 131 cardiovascular disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 45 | $1,105,545 |
| EliquisApixaban | 293 | $322,315 |
| CamzyosMavacamten | 19 | $153,548 |
| EntrestoSacubitril/Valsartan | 109 | $90,606 |
| Repatha SureclickEvolocumab | 126 | $87,948 |
| XareltoRivaroxaban | 50 | $53,434 |
| JardianceEmpagliflozin | 20 | $26,252 |
| FarxigaDapagliflozin Propanediol | 27 | $24,957 |
| ClopidogrelClopidogrel Bisulfate | 276 | $3,962 |
| Atorvastatin Calcium | 278 | $3,481 |
| Rosuvastatin Calcium | 120 | $3,224 |
| Flecainide Acetate | 76 | $3,153 |
| Potassium Chloride | 142 | $3,019 |
| Metoprolol Succinate | 187 | $2,703 |
| Ranolazine ErRanolazine | 27 | $2,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $1,127 | $1,427,860338 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $260 | $153,54819 claims |
| NovartisEntresto | $493 | $90,606109 claims |
| Johnson & JohnsonXarelto | $528 | $53,43450 claims |
| Boehringer IngelheimJardiance | $438 | $26,25220 claims |
| AstraZenecaFarxiga | $213 | $24,95727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 131 cardiovascular disease providers in Utah.
Other cardiovascular disease in Provo
- Marvin AllenProvo$9K
- Stephen WilkinsonProvo$8K
- Phanindra AntharamProvo$6K
- Hussein DaoudProvo$3K
- John RyanSalt Lake City$1.4M
- Robert FowlesSalt Lake City$611K
- Brian WhisenantMurray$416K
- Andrew BehuninDraper$192K
- Jeffrey OsbornSalt Lake City$69K
- James FangSalt Lake City$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.